Journal of Thrombosis and Thrombolysis

, Volume 48, Issue 3, pp 514–515 | Cite as

Genetic factors affecting thrombosis in patients with essential thrombocythemia by heparin treatment

  • Tomoyuki KawadaEmail author
Letter to the Editor


Compliance with ethical standards

Conflict of interest

The author has no conflict of interest in this study.


  1. 1.
    Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L (2019) Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. J Thromb Thrombolysis 47(1):155–156. CrossRefGoogle Scholar
  2. 2.
    Larsen ML, Pedersen OH, Hvas AM et al (2019) Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets 30(3):322–328. CrossRefGoogle Scholar
  3. 3.
    Zhou D, Chen W, Cheng H et al (2018) Clinico-hematological profile and thrombotic/hemorrhagic events in 150 Chinese patients with essential thrombocythemia. Leuk Res 69:1–6. CrossRefGoogle Scholar
  4. 4.
    Buxhofer-Ausch V, Steurer M, Sormann S et al (2019) Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. Eur J Haematol. Google Scholar
  5. 5.
    Samuelson B, Chai-Adisaksopha C, Garcia D (2015) Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. J Thromb Thrombolysis 40(4):474–479. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hygiene and Public HealthNippon Medical SchoolTokyoJapan

Personalised recommendations